Results 201 to 210 of about 29,093 (266)

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 7, Page 1502-1516, April 2026.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy   +10 more
wiley   +1 more source

Mitochondrial Ca2+ overload is a pivotal risk factor for lethal ventricular arrhythmias due to the oxidation of mitochondrial respirasome and energetic failure

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 7, Page 1404-1426, April 2026.
The data that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions. Background and Purpose Ventricular arrhythmias are a leading cause of death among patients with cardiovascular diseases and are associated with elevated ...
Felipe de Jesús Salazar‐Ramírez   +13 more
wiley   +1 more source

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2661-2671, April 2026.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan   +7 more
wiley   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3137-3145, April 2026.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen   +7 more
wiley   +1 more source

Factor XI and Heart Failure. [PDF]

open access: yesArterioscler Thromb Vasc Biol
Gailani D.
europepmc   +1 more source

The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease

open access: yesJournal of Internal Medicine, Volume 299, Issue 4, Page 444-466, April 2026.
Abstract Increased urinary albumin excretion is a strong predictor for cardiovascular events in persons with and without decreased glomerular filtration rate and can be assessed with the urinary albumin‐to‐creatinine ratio (UACR), which is a selective, sensitive, and convenient method for patients.
Holly J. Kramer, George L. Bakris
wiley   +1 more source

Reversible Atrial Fibrillation and Cardiogenic Shock Following Acute Aluminum Phosphide Poisoning: A Case Report and Literature Review. [PDF]

open access: yesClin Med Insights Case Rep
Mengistie CT   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy